The authors believe that future research should head in two directions. The first direction taken should involve establishing a PNS compounds library to correlate their functions with structures; the second direction should be by integrating network pharmacology and pharmaceutical techniques in the future development of these natural compounds as new vascular medicine.

To discover effective agents for AD treatment, one promising strategy is to integrate various technology clusters related to anti-AD drugs in terms of the extremely dispersed patent citation network in this area. In this context, governments should pay more attention to encourage basic research, especially to focus on cross-mechanism anti-AD agents. New theories and targets for AD, such as the tau protein hypothesis, are worthy of researcher note. Drugs targeting β-amyloid peptide theory show promise for investors.

No abstract